Stryker Corporation (SYK)

FairStock Score: 60/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that can earn high returns and keep improving, and Stryker is a good medical-technology franchise. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported revenue of $6.6B, net income of $1.3B, and diluted EPS of $3.30. For fiscal 2025 it earned $3.2B on $25.1B of revenue, or $8.40 per diluted share, versus $3.0B on $22.6B and $7.76 in fiscal 2024. That is respectable growth, though fiscal 2025 net income was only modestly above fiscal 2023’s $3.2B, so the earnings record is not perfectly smooth. FairStock’s Lynch category calls it a STALWART, based on 15.2% yearly profit growth and 11.8% revenue growth over five years, and its FairStock Score is 60/100. The balance sheet looks sound: Piotroski 7/9, Altman 4.04, debt/equity 0.64, and trailing FCF of $4.7B. But at the $306.13 close on 2026-10-26, FairStock’s P/E is 31.69, P/B 4.89, EV/EBITDA 18.47, and FCF yield 4.0%. Its Graham Number is $116.59, leaving a negative margin of safety of 163.44%. ROE is 16.51%, but ROCE is only 8.16%. This is a quality stalwart with a durable medical-device position, yet the price already discounts a lot of steady compounding. I would want a wider gap between price and intrinsic value before calling it a Graham-style bargain.

In plain English: Stryker makes medical equipment, surgical products, and orthopaedic implants. The business looks strong: revenue and profit are growing, cash flow is solid, and the latest quarter showed a meaningful profit. The share price looks high compared with the profits and assets the company currently reports.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q4 2025 10-K (period ended 2025-12-31) · fiscal Q3 2025 10-K (period ended 2025-09-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer